as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹188.4
Change
-1.02 (-0.54%)
Open
₹192.5
Prev. Close
₹189.42
Day High
₹192.8
Day Low
₹188.0
Volume Analysis
Traded
1,595
Delivered
1,364
Delivery %
85.52%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (1)
- •Low return on equity (3.17%)
Opportunities (0)
No signal for this stock
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹196.26 | ₹194.53 | ₹191.46 | ₹189.73 | ₹186.66 | ₹184.93 | ₹181.86 |
| Fibonacci | ₹194.53 | ₹192.7 | ₹191.56 | ₹189.73 | ₹187.9 | ₹186.76 | ₹184.93 |
| Camarilla | ₹189.72 | ₹189.28 | ₹188.84 | ₹189.73 | ₹187.96 | ₹187.52 | ₹187.08 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
—
1 Week
-1.03%
1 Month
-5.2%
3 Months
—
6 Months
—
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹105.38
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
14.29%
Net margin 7.43% × asset turnover 0.84x × equity multiplier 2.29x
Company Overview
Sector
Healthcare
Market Cap
₹107 Cr
P/E (TTM)
31.4
ROE
3.17%
Book Value
₹124.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 23 Sep 2026. Not investment advice.
TopFund Analysis
Makers Laboratories Ltd. lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 58/100. The strongest factor is Financial Strength (100/100), while Institutional Ownership (30/100) is the weakest area to weigh before deciding. Notably: Low return on equity (3.17%).
TopFund Score — Fundamentals Quality
58/100 — AverageData confidence: 74/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Liquidity
From Screener.in
- +Company has delivered good profit growth of 49.3% CAGR over last 5 years
- +Debtor days have improved from 68.8 to 51.6 days.
- −Though the company is reporting repeated profits, it is not paying out dividend
- −Company has a low return on equity of -2.05% over last 3 years.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
CARE Edge reaffirmed BBB+ Stable rating for Rs 8 crore long-term bank facilities.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 25 | 25 | 27 | 28 | 30 | 30 | 28 | 34 | 35 | 34 | 36 | 36 | 43 |
| Expenses + | 25 | 25 | 26 | 27 | 28 | 27 | 26 | 31 | 32 | 32 | 32 | 30 | 36 |
| Operating Profit | 0 | 0 | 0 | 1 | 2 | 2 | 1 | 3 | 3 | 2 | 4 | 5 | 7 |
| OPM % | -0.56% | 0.8% | 0.75% | 3.09% | 6.12% | 7.41% | 4.73% | 9.12% | 8.6% | 6.67% | 11.66% | 14.77% | 16.27% |
| Other Income + | 0 | 0 | 0 | 0 | -1 | 11 | 1 | 0 | 0 | 0 | 0 | 1 | 1 |
| Interest | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | -1 | -1 | -1 | 0 | 0 | 11 | 1 | 2 | 2 | 1 | 3 | 5 | 6 |
| Tax % | 18.44% | 10.89% | -4.46% | 152.63% | 48.94% | 11.98% | 60.29% | 24.64% | 34.85% | 42.64% | 27.94% | 24.89% | 27.03% |
| Net Profit + | -2 | -1 | -1 | -1 | -1 | 10 | 0 | 2 | 1 | 1 | 2 | 4 | 5 |
| EPS in Rs | -4 | -2 | -3 | -2 | -2 | 15 | -1 | 0 | 1 | 0 | 2 | 2 | 3 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|
| Sales + | 69 | 127 | 101 | 104 | 121 | 141 | 148 |
| Expenses + | 60 | 108 | 98 | 103 | 112 | 126 | 130 |
| Operating Profit | 8 | 19 | 3 | 1 | 9 | 15 | 19 |
| OPM % | 12.0% | 15.0% | 3.3% | 1.1% | 7.0% | 11.0% | 13.0% |
| Other Income + | 1 | 3 | 2 | 2 | 11 | 2 | 2 |
| Interest | 2 | 2 | 2 | 2 | 1 | 1 | 1 |
| Depreciation | 5 | 4 | 4 | 5 | 5 | 5 | 5 |
| Profit before tax | 3 | 16 | -1 | -4 | 13 | 11 | 15 |
| Tax % | 50.0% | 25.0% | 161.0% | 23.0% | 19.0% | 30.0% | — |
| Net Profit + | 1 | 12 | -2 | -5 | 11 | 8 | 11 |
| EPS in Rs | -1 | 8 | -8 | -11 | 13 | 4 | 6 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Reserves | 49 | 55 | 63 | 57 | 65 | 67 |
| Borrowings + | 21 | 23 | 17 | 22 | 8 | 9 |
| Other Liabilities + | 62 | 62 | 66 | 76 | 70 | 85 |
| Total Liabilities | 136 | 144 | 152 | 161 | 148 | 167 |
| Fixed Assets + | 71 | 68 | 85 | 87 | 74 | 71 |
| CWIP | 0 | 9 | 0 | 0 | 1 | 4 |
| Investments | 2 | 0 | 0 | 3 | 0 | 12 |
| Other Assets + | 63 | 66 | 67 | 71 | 73 | 81 |
| Total Assets | 136 | 144 | 152 | 161 | 148 | 167 |
| Equity Capital | 5 | 5 | 6 | 6 | 6 | 6 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 0 | 18 | -9 | 1 | -4 | 14 |
| Cash from Investing Activity + | 0 | -22 | 1 | -7 | 20 | -15 |
| Cash from Financing Activity + | 0 | 0 | 6 | 6 | -16 | 0 |
| Net Cash Flow | 0 | -3 | -2 | 0 | 0 | 0 |
| CFO/OP | 0 | 128 | -185 | 232 | -20 | 118 |
| Free Cash Flow | 0 | 9 | -21 | -6 | 11 | 11 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 38.73% | 38.74% | 38.73% | 38.74% | 38.73% | 38.33% | 38.34% | 38.35% | 38.35% | 38.35% | 38.34% | 38.34% |
| Promoters | 61.28% | 61.28% | 61.28% | 61.28% | 61.28% | 61.28% | 61.28% | 61.28% | 61.28% | 61.28% | 61.28% | 61.28% |
| DII | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.39% | 0.39% | 0.39% | 0.39% | 0.39% | 0.39% | 0.39% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Makers Laboratories Ltd. (this stock) | 107 | 31.4 | 1.48 | 3.17% |
| Vaishali Pharma Limited | 112 | 25.2 | 1.63 | 6.02% |
| Alpa Laboratories Ltd | 124 | 30.6 | 0.67 | 8.39% |
| Balaxi Pharma Ltd | 126 | 52.0 | 0.51 | 0.59% |
| Sunil Healthcare Ltd. | 78 | 21.1 | 1.12 | 6.01% |
| Parnax Lab Ltd. | 149 | 14.8 | 1.56 | 14.4% |
| Mangalam Drug & Chem Ltd | 50 | — | 0.49 | -35.2% |
Which Mutual Funds Hold Makers Laboratories Ltd.?
Frequently Asked Questions about Makers Laboratories Ltd.
Makers Laboratories Ltd. (MAKERSL) closed at ₹188.4 on NSE on 25 September 2026, down 1.02 (0.54%) from the previous close.
Makers Laboratories Ltd. trades on the NSE (National Stock Exchange of India) under the symbol MAKERSL.
Makers Laboratories Ltd. has a trailing twelve-month P/E (price-to-earnings) ratio of 31.4.
Makers Laboratories Ltd. has a dividend yield of 0.0%.
Makers Laboratories Ltd.'s 52-week high is ₹237.0 and its 52-week low is ₹109.0.
Makers Laboratories Ltd. has a market capitalisation of ₹107 crore.
Makers Laboratories Ltd. has a TopFund Quality Score of 58/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Makers Laboratories Ltd.?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.